PDD Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since April 2023 — Data Talk
PDD Holdings Inc. Sponsored ADR Class A (PDD) is currently at $140.86, down $0.67 or 0.47%
--Would be lowest close since May 14, 2024, when it closed at $138.69
--Currently down seven consecutive days; down 6.76% over this period
--Longest losing streak since April 12, 2023, when it fell for eight straight trading days
--Worst seven day stretch since the seven days ending June 5, 2024, when it fell 9.37%
--Down 5.96% month-to-date; on pace for worst month since March 2024, when it fell 6.66%
--Down 3.72% year-to-date
--Down 30.55% from its all-time closing high of $202.82 on Feb. 17, 2021
--Up 96.51% from 52 weeks ago (June 27, 2023), when it closed at $71.68
--Down 10.6% from its 52-week closing high of $157.57 on May 24, 2024
--Up 108.1% from its 52-week closing low of $67.69 on July 6, 2023
--Traded as low as $139.70; lowest intraday level since May 15, 2024, when it hit $137.73
--Down 1.29% at today's intraday low
All data as of 1:47:07 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
June 25, 2024 14:04 ET (18:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks